Amend Surgical is a product development company offering differentiated biologic solutions for medical device manufacturers and distributors. Amend is targeting the global bone graft substitute market with licensed, patented, technology and is focused on spine, orthopedic and dental indications. Our R&D pipeline includes products loaded with antibiotics and bone morphogenic proteins. Additionally, we are commercializing a novel Biomimetic Bone technology licensed from the University of Florida that offers the hope for a synthetic graft with load bearing capability and osteostimulative properties. Our foundation product line, NanoFUSE® Bioactive Matrix, is a patent protected bone graft substitute that is the only combination bone grafting product currently approved by the FDA for use in spine and orthopedics.